Drug Profile
NEO101 - LEO Pharma
Alternative Names: NEO-101 - LEO PharmaLatest Information Update: 20 Jun 2016
Price :
$50
*
At a glance
- Originator Neosil
- Developer LEO Pharma
- Class Anti-infectives; Biguanides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne; Atopic dermatitis; Bacterial infections; Burns; Staphylococcal infections